administration of allogeneic-msc in patients with non-ischemic dilated cardiomyopathy

Conditions: Non-ischemic Dilated Cardiomyopathy

Summary: the purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.


Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. men and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form. 2. diagnosis of nidcm with left ventricular ejection fraction ≤45%. 3. appropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. at a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ace) inhibitors or angiotensin receptor blockers (arbs) or angiotensin receptor neprilysin inhibitors (arni) or have appropriate medical indication precluding use of one or both of these agents. subjects must be on a stable regimen for at least 30 days prior to the procedure. dose titration is allowed. 4. be a candidate for cardiac catheterization\* 5. be willing to undergo dna test. exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy 2. clinical manifestation of coronary artery disease (cad) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac mri suggestive of undiagnosed cad or history of percutaneous coronary intervention (pci) or coronary artery bypass surgery (cabg). be indicated for or require coronary artery revascularization 3. documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries 4. valvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent\* 5. aortic stenosis with valve area ≤ 1.5cm2\* 6. cardiomyopathy due to acute post-partum (within 6 months), non-compaction\*, or hypertrophic\* cardiomyopathy 7. cardiomyopathy due to known toxin (e.g amyloid) note: anthracycline induced cardiomyopathy will be allowed 8. qtc interval \> 550 ms on baseline electrocardiogram (ecg) (note: qtc interval is the interval between the start of the q wave and the end of the t wave in the heart's electrical cycle) 9. automated implantable cardioverter defibrillator (aicd) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent 10. have an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff 11. a hematologic abnormality during baseline testing as evidenced by hemoglobin \< 9 g/dl; hematocrit \< 30%; absolute neutrophil count \< 2,000 or total wbc count more than 2 times upper limit of normal; or platelet values \< 100,000/ul 12. have liver dysfunction, as evidenced by enzymes aspartate transaminase enzyme (ast) and alanine aminotransferase enzyme (alt) greater than three times the uln 13. have a bleeding diathesis or coagulopathy (international normalised ratio (inr) \> 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions 14. be a solid organ transplant recipient. this does not include prior cell based therapy (\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. 15. have a history of organ or cell transplant rejection 16. have a clinical history of malignancy within the past 12 months (i.e., subjects with prior malignancy must be disease free for 12 months), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma 17. drug and/or alcohol abuse or dependence within the past 9 months 18. be serum positive for hiv, hepatitis b surface antigen, or viremic hepatitis c 19. documented presence of a known left ventricular (lv) thrombus, aortic dissection, or aortic aneurysm. (refer to "guidance to the pi" section with regards to lv thrombus, below)\* 20. blood glucose levels (hba1c) \>10% 21. severe radiographic contrast allergy 22. known history of anaphylactic reaction to penicillin or streptomycin 23. hypersensitivity to dimethyl sulfoxide (dmso) 24. non-cardiac condition with life expectancy \< 1 year 25. acute stroke or transient ischemic attack within 3 months of enrollment 26. be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods 27. pacemaker-dependence with an implantable cardioverter defibrillator (icd) (note: pacemaker-dependent candidates without an icd are not excluded) 28. presence of a pacemaker and/or icd generator with any of the following limitations/conditions: * manufactured before the year 2000 * leads implanted \< 6 weeks prior to consent * non-transvenous epicardial or abandoned leads * subcutaneous icds * leadless pacemakers 29. a cardiac resynchronization therapy (crt) device implanted less than 3 months prior to consent 30. other mri contraindications (e.g. subject body habitus incompatible with mri) 31. need for advanced heart failure therapy (e.g. iv inotropes) 32. be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial 33. any other condition that in the judgment of the investigator would be a contraindication to enrollment or follow-up (\*) applies to subjects receiving product via transendocardial administration only

Keywords: allogeneic mesenchymal stem cells bone marrow-derived mesenchymal stem cells